FI86887B - Fusionsprotein, foerfarande foer deras framstaellning och deras anvaendning. - Google Patents
Fusionsprotein, foerfarande foer deras framstaellning och deras anvaendning. Download PDFInfo
- Publication number
- FI86887B FI86887B FI863041A FI863041A FI86887B FI 86887 B FI86887 B FI 86887B FI 863041 A FI863041 A FI 863041A FI 863041 A FI863041 A FI 863041A FI 86887 B FI86887 B FI 86887B
- Authority
- FI
- Finland
- Prior art keywords
- sequence
- amino acids
- fusion protein
- plasmid
- dna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (12)
1. Fusionsprotein, kännetecknat där-av, att det har den allmänna formeln 5 Met-Xn-D' -Y-Z, där n är noil eller 1; X är en sekvens av 1 - 12 gene-tiskt kodbara aminosyror; D' är en sekvens av ca 70 ami-10 nosyror inom aminosyrasekvensomrädet 23 - 93 hos D-pepti-den i trp-operonen i E. coli; Y är en sekvens av en eller flere genetiskt kodbara aminosyror, vilken möjliggör en avspjälkning av päföljande aminosyrasekvens Z; och Z är en sekvens av genetiskt kodbara aminosyror.
2. Fusionsprotein enligt patentkravet 1, kän netecknat därav, att n är 1 och X omfattar högst 5 aminosyror, varvid den N-terminala sekvensen i sekven-sen X företrädesvis är Lys-Ala.
3. Fusionsprotein enligt patentkravet 1 eller 2, 20 kännetecknat därav, att Y innehäller den C-terminala gruppen Met, Cys, Trp, Arg, Lys eller nägon ur grupperna (Asp)m-Pro, Glu-(Asp)m-Pro eller Ile-Glu-Gly-Arg, varvid m är 1,2 eller 3, eller bestär av dessa aminosyror eller nägon av dessa grupper.
4. Fusionsprotein enligt ett eller flere av före- gäende patentkrav, kännetecknat därav, att Z betecknar aminosyrasekvensen i humant proinsulin eller ett hirudin.
5. Förfarande för framställning av fusionsprotei-30 net enligt ett eller flere av patentkraven 1-4, kännetecknat därav, att genstrukturen, som kodar detta fusionsprotein uttrycks i en bakterievärdcell, företrädesvis i E. coli och fusionsproteinet avskiljs.
6. Förfarande enligt patentkravet 5, k ä n n e -35 tecknat därav, att i genstrukturen kodar DNA-sek- 26 8 6 8 S 7 vensen I (bilaga) för D', och/eller i genstrukturen kodar DNA-sekvensen (kodande sträng) 5' AAA GCA AAG GGC 3' för X, och/eller genstrukturen väljs sä, att fusionspro-5 telnet är olösligt, och/eller genstrukturen innefattas i fas 1 en vektor, som av trp-operonen i E. coli innehäller promotorn, operatorn och ribosombindningsstället för L-peptiden.
7. Förfarande enligt patentkravet 6, k ä n n e -10 tecknat därav, att vektorn är ett derivat av pBR322, väri avsnittet frän Hindlll-stället i position 29 tili PvuII-stället i position 2066 avlägsnats ur pBR322-DNA:t.
8. Genstruktur, kännetecknad därav, 15 att den kodar fusionsproteiner enligt patentkraven 1-4.
9. Vektor, företrädesvis ett derivat av plasmiden pBR322, väri avsnittet frän Hindlll-stället i position 29 tili PvuII-stället i position 2066 avlägsnats ur pBR322-DNA:t, kännetecknat därav, att den innehäller 20 genstrukturen enligt patentkravet 8.
10. Expressionssystem för bakterievärdceller, företrädesvis ett E, coli-system, kännetecknat därav, att det innehäller en vektor enligt patentkravet 9. 25
11. Förfarande för framställning av ett eukaryo- tiskt protein, kännetecknat därav, att man ur ett fusionsprotein enligt patentkraven 1-4 avspjälker aminosyrasekvensen Z kemiskt eller enzymatiskt.
12. Plasmid, kännetecknad därav, att 30 den är pH154/25 (figur 3), pH254 (figur 4), pH255 (figur 4), pH256 (figur 5), pH257 (figur 5), pH120/14 (figur 1), pKl50 (figur 7), pK160 (figur 8), pK170 (figur 9), pK180 (figur 10), pHl54/25* (figur 11), pH256*, vilken motsva-rar pH256 i figur 5 varur fragmentet som erhällits med 35 PvuII avlägsnats säsom visas i figur 11, pH120/14* vilken 27 868 S7 motsvarar pH120/14 i figur 1, varur fragmentet som erhäl-lits med Pvull avlägsnats säsom visas i figur 11, pK150*, som motsvarar pK 150 i figur 7, varur fragmentet som er-hällits med Pvull avlägsnats säsom visas i figur 11, 5 pK170*, som motsvarar pK170 i figur 9, varur fragmentet som erhällits med Pvull avlägsnats säsom visas i figur 11, eller plntl3 (figur 12). t
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3526995 | 1985-07-27 | ||
| DE19853526995 DE3526995A1 (de) | 1985-07-27 | 1985-07-27 | Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI863041A0 FI863041A0 (fi) | 1986-07-24 |
| FI863041A FI863041A (fi) | 1987-01-28 |
| FI86887B true FI86887B (fi) | 1992-07-15 |
| FI86887C FI86887C (sv) | 1992-10-26 |
Family
ID=6276985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI863041A FI86887C (sv) | 1985-07-27 | 1986-07-24 | Fusionsprotein, förfarande för deras framställning och deras användnin g |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0211299B1 (sv) |
| JP (1) | JPH07113040B2 (sv) |
| KR (1) | KR950000299B1 (sv) |
| AT (1) | ATE50596T1 (sv) |
| AU (1) | AU595221B2 (sv) |
| CA (1) | CA1336329C (sv) |
| DE (2) | DE3526995A1 (sv) |
| DK (1) | DK172618B1 (sv) |
| ES (1) | ES2000278A6 (sv) |
| FI (1) | FI86887C (sv) |
| GR (1) | GR861957B (sv) |
| HU (1) | HU197356B (sv) |
| IE (1) | IE59127B1 (sv) |
| IL (1) | IL79522A (sv) |
| NO (1) | NO175640C (sv) |
| NZ (1) | NZ216967A (sv) |
| PT (1) | PT83065B (sv) |
| ZA (1) | ZA865556B (sv) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3738541A1 (de) * | 1987-11-13 | 1989-05-24 | Hoechst Ag | Verfahren zur isolierung und reinigung von hirudin |
| DE3541856A1 (de) * | 1985-11-27 | 1987-06-04 | Hoechst Ag | Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens |
| EP0237338B1 (en) * | 1986-03-12 | 1992-09-23 | IMCERA Group Inc. | Hybrid expression vectors, their construction and uses |
| EP0371041A1 (en) * | 1987-06-24 | 1990-06-06 | Novo Nordisk A/S | A process for preparing a protein or polypeptide, a dna sequence coding for the polypeptide, a microorganism containing the dna sequence as well as the polypeptide and its use as a pharmaceutical preparation |
| US5179196A (en) * | 1989-05-04 | 1993-01-12 | Sri International | Purification of proteins employing ctap-iii fusions |
| US5227293A (en) * | 1989-08-29 | 1993-07-13 | The General Hospital Corporation | Fusion proteins, their preparation and use |
| US5358857A (en) * | 1989-08-29 | 1994-10-25 | The General Hospital Corp. | Method of preparing fusion proteins |
| IL95495A (en) * | 1989-08-29 | 1996-10-16 | Hoechst Ag | Fusion proteins their preparation and use |
| GB8927722D0 (en) * | 1989-12-07 | 1990-02-07 | British Bio Technology | Proteins and nucleic acids |
| DE3942580A1 (de) * | 1989-12-22 | 1991-06-27 | Basf Ag | Verfahren zur herstellung von hirudin |
| DE59711533D1 (de) | 1996-07-26 | 2004-05-27 | Aventis Pharma Gmbh | Insulinderivate mit erhöhter Zinkbindung |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| DE19825447A1 (de) | 1998-06-06 | 1999-12-09 | Hoechst Marion Roussel De Gmbh | Neue Insulinanaloga mit erhöhter Zinkbildung |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| WO2009066320A2 (en) | 2007-09-21 | 2009-05-28 | Cadila Healthcare Limited | Fusion protein systems suitable for high expression of peptides |
| EP3228320B1 (de) | 2008-10-17 | 2019-12-18 | Sanofi-Aventis Deutschland GmbH | Kombination von einem insulin und einem glp-1-agonisten |
| AR080669A1 (es) | 2009-11-13 | 2012-05-02 | Sanofi Aventis Deutschland | Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina |
| UY33025A (es) | 2009-11-13 | 2011-06-30 | Sanofi Aventis Deustschland Gmbh | Composicion farmaceutica que comprende un agonista de glp-1 metionina |
| MX339614B (es) | 2010-08-30 | 2016-06-02 | Sanofi - Aventis Deutschland GmbH | Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2. |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| RU2650616C2 (ru) | 2011-08-29 | 2018-04-16 | Санофи-Авентис Дойчланд Гмбх | Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| KR20200080748A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법 |
| KR20200080747A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA802992B (en) * | 1979-06-01 | 1981-10-28 | Univ California | Human pre-growth hormone |
| ZA811368B (en) * | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| JPS62502586A (ja) * | 1985-03-18 | 1987-10-08 | ジ−ン ラブズ，インコ−ポレイテツド | ハイブリツド遺伝子カセツトベクタ− |
| GB8507666D0 (en) * | 1985-03-25 | 1985-05-01 | Wellcome Found | Epidermal growth factor production |
| GR860915B (en) * | 1985-04-08 | 1986-07-11 | Genetic Systems Corp | Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to lav |
-
1985
- 1985-07-27 DE DE19853526995 patent/DE3526995A1/de not_active Withdrawn
-
1986
- 1986-07-19 AT AT86109945T patent/ATE50596T1/de active
- 1986-07-19 EP EP86109945A patent/EP0211299B1/de not_active Expired - Lifetime
- 1986-07-19 DE DE8686109945T patent/DE3669175D1/de not_active Expired - Lifetime
- 1986-07-24 ES ES8600544A patent/ES2000278A6/es not_active Expired
- 1986-07-24 FI FI863041A patent/FI86887C/sv not_active IP Right Cessation
- 1986-07-25 NZ NZ216967A patent/NZ216967A/xx unknown
- 1986-07-25 ZA ZA865556A patent/ZA865556B/xx unknown
- 1986-07-25 AU AU60565/86A patent/AU595221B2/en not_active Expired
- 1986-07-25 CA CA000514682A patent/CA1336329C/en not_active Expired - Lifetime
- 1986-07-25 DK DK198603554A patent/DK172618B1/da not_active IP Right Cessation
- 1986-07-25 IL IL79522A patent/IL79522A/xx not_active IP Right Cessation
- 1986-07-25 HU HU863100A patent/HU197356B/hu unknown
- 1986-07-25 PT PT83065A patent/PT83065B/pt unknown
- 1986-07-25 GR GR861957A patent/GR861957B/el unknown
- 1986-07-25 NO NO863000A patent/NO175640C/no unknown
- 1986-07-25 IE IE197786A patent/IE59127B1/en not_active IP Right Cessation
- 1986-07-26 JP JP61176558A patent/JPH07113040B2/ja not_active Expired - Lifetime
- 1986-07-26 KR KR1019860006142A patent/KR950000299B1/ko not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FI863041A (fi) | 1987-01-28 |
| DK355486A (da) | 1987-01-28 |
| KR950000299B1 (ko) | 1995-01-13 |
| EP0211299A3 (en) | 1988-06-01 |
| DE3669175D1 (de) | 1990-04-05 |
| DE3526995A1 (de) | 1987-02-05 |
| FI863041A0 (fi) | 1986-07-24 |
| JPS6229600A (ja) | 1987-02-07 |
| DK172618B1 (da) | 1999-03-01 |
| JPH07113040B2 (ja) | 1995-12-06 |
| NO863000D0 (no) | 1986-07-25 |
| PT83065A (de) | 1986-08-01 |
| IE861977L (en) | 1987-01-27 |
| ES2000278A6 (es) | 1988-02-01 |
| EP0211299B1 (de) | 1990-02-28 |
| IE59127B1 (en) | 1994-01-12 |
| IL79522A (en) | 1991-08-16 |
| NZ216967A (en) | 1988-08-30 |
| EP0211299A2 (de) | 1987-02-25 |
| HUT43629A (en) | 1987-11-30 |
| NO175640B (sv) | 1994-08-01 |
| IL79522A0 (en) | 1986-10-31 |
| GR861957B (en) | 1986-11-25 |
| PT83065B (pt) | 1989-02-28 |
| DK355486D0 (da) | 1986-07-25 |
| FI86887C (sv) | 1992-10-26 |
| KR870001312A (ko) | 1987-03-13 |
| NO863000L (no) | 1987-01-28 |
| ZA865556B (en) | 1987-03-25 |
| CA1336329C (en) | 1995-07-18 |
| ATE50596T1 (de) | 1990-03-15 |
| AU6056586A (en) | 1987-01-29 |
| AU595221B2 (en) | 1990-03-29 |
| HU197356B (en) | 1989-03-28 |
| NO175640C (no) | 1994-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI86887B (fi) | Fusionsprotein, foerfarande foer deras framstaellning och deras anvaendning. | |
| IL95495A (en) | Fusion proteins their preparation and use | |
| JP2694840B2 (ja) | ポリペプチドを微生物により発現させる方法 | |
| US4366246A (en) | Method for microbial polypeptide expression | |
| EP0234888B1 (en) | Process for producing human epidermal growth factor and analogs thereof | |
| Kuliopulos et al. | Production, purification, and cleavage of tandem repeats of recombinant peptides | |
| DK172210B1 (da) | Hirudinderivater | |
| US4356270A (en) | Recombinant DNA cloning vehicle | |
| US4425437A (en) | Microbial polypeptide expression vehicle | |
| US4431739A (en) | Transformant bacterial culture capable of expressing heterologous protein | |
| US5648244A (en) | Production, purification, cleavage and use of fusion peptides | |
| CA1297813C (en) | Process for production of insulin-like growth factor i | |
| Sung et al. | Short synthetic oligodeoxyribonucleotide leader sequences enhance accumulation of human proinsulin synthesized in Escherichia coli. | |
| US6051399A (en) | Production of C-terminal amidated peptides from recombinant protein constructs | |
| IE57664B1 (en) | The preparation of polypeptides having an amide carboxyl terminal end | |
| US5545564A (en) | Vector for expression and secretion of polypeptide microorganism transformed by the vector and production of polypeptide with the same microorganism | |
| US4711847A (en) | Preparation of secretin | |
| Kempe et al. | Production and characterization of growth hormone releasing factor analogs through recombinant DNA and chemical techniques | |
| JPH0816120B2 (ja) | 成長ホルモン放出因子を含むハイブリドポリペプチド | |
| IE852440L (en) | Signal for protein transport | |
| FI97549C (sv) | Förfarande för framställning av främmande proteiner i Streptomycesceller | |
| SU1707078A1 (ru) | Рекомбинантна плазмидна ДНК рТНУЗ14, кодирующа полипептид со свойствами тимозина @ человека, рекомбинантна плазмидна ДНК рТНУ12 - промежуточный продукт дл ее конструировани и штамм бактерий ЕSснеRIснIа coLI - продуцент полипептида со свойствами тимозина @ человека | |
| NZ229748A (en) | Process of producing a protein from a precursor having an n-terminal pro by enzymatic cleavage | |
| FI97239B (sv) | Förfarande för framställning av fusionprotein | |
| KR840002106B1 (ko) | 세균숙주의 형질전환에 적합한 재조합 클로닝 베히클의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Owner name: HOECHST AKTIENGESELLSCHAFT |
|
| MA | Patent expired |